1997年中山醫(yī)科大學(xué)臨床醫(yī)學(xué)系畢業(yè)，直接留校后在中山一院歷任住院醫(yī)師，主治醫(yī)師，副主任醫(yī)師。獲腫瘤學(xué)碩士學(xué)位，長(zhǎng)期工作在醫(yī)療、教學(xué)、科研第一線，積累了豐富的腫瘤診治臨床經(jīng)驗(yàn)。擅長(zhǎng)常見腫瘤的診斷以及化療、靶向治療、生物免疫治療等腫瘤內(nèi)科治療，熟悉肺癌、乳腺癌、胃癌、結(jié)直腸癌、膽管癌、胰腺癌、前列腺癌、食管癌、肝癌、黑色素瘤、軟組織肉瘤及淋巴瘤等全身各部位惡性腫瘤的全面病情評(píng)估、最新進(jìn)展與綜合治療，對(duì)晚期惡性腫瘤病人以姑息止痛治療、營(yíng)養(yǎng)支持治療為主的綜合治療有豐富的經(jīng)驗(yàn)。尤其對(duì)各種腫瘤并發(fā)癥處理，減輕化療毒副放應(yīng)等方面有獨(dú)特經(jīng)驗(yàn)。研究方向：全身各部位惡性腫瘤的根治性化療、新輔助化療、輔助化療、同期化療放療、化療聯(lián)合靶向治療、化療聯(lián)合生物細(xì)胞免疫治療以及晚期腫瘤的姑息治療、靶向治療、免疫治療。尤其是肺癌、乳腺癌、胃腸道惡性腫瘤的綜合治療。主要教育和工作經(jīng)歷：1992.9—1997.6中山醫(yī)科大學(xué)臨床醫(yī)學(xué)系本科2009.9—2012.6中山大學(xué)腫瘤學(xué)碩士1997.7—2002.6中山大學(xué)附屬第一醫(yī)院住院醫(yī)師2002.6—2015.12中山大學(xué)附屬第一醫(yī)院主治醫(yī)師2016.1至今中山大學(xué)附屬第一醫(yī)院副主任醫(yī)師社會(huì)兼職：◆廣東省抗癌協(xié)會(huì)癌癥康復(fù)與姑息治療專業(yè)委員會(huì)青年委員◆廣東省健康管理學(xué)會(huì)腫瘤防治專業(yè)委員會(huì)委員◆廣州抗癌協(xié)會(huì)胃癌專業(yè)委員會(huì)委員論著：A：第一作者/共同第一/通訊作者1)Poly(AT)deletion/insertionpolymorphismoftheXPCgenecontributestourinarysystemcancersusceptibility:Ameta-analysis.Gene,2013,Oct10;528(2):335-42.(IF=2.138)第一作者/通訊作者2)XPCgenepolymorphismscontributetobladdercancersusceptibility:ameta-analysis.TumourBiol,2014Jan;35(1):447-53.(IF=3.611)第一作者/通訊作者3)XerodermapigmentosumcomplementationgroupD(XPD)genepolymorphismscontributetobladdercancerrisk:ameta-analysis.TumourBiol,2014Apr;35(4):3905-15.(IF=3.611)4)AnovelroleformicroRNA-129-5pininhibitingovariancancercellproliferationandsurvivalviadirectsuppressionoftranscriptionalco-activatorsYAPandTAZ.Oncotarget,2015Apr20;6(11):8676-86.(IF=6.359)5)Osterixtranscriptionalfactorisinvolvedinthemetastasisofhumanbreastcancers.OncolLett,2015Sep;10(3):1870-1874.(IF=1.554)6)Hypertensionasapredictivebiomarkerforefficacyofbevacizumabtreatmentinmetastaticcolorectalcancer:Ameta-analysis.JBUON,2014Dec;19(4):917-24.(IF=0.741)通訊作者7)Transarterialchemoembolizationvs.conservativetreatmentforunresectableinfiltratinghepatocellularcarcinoma:Aretrospectivecomparativestudy.MolClinOncol,2014Nov;2(6):1047-1054.8)TheGlasgowPrognosticScorepredictspoorsurvivalincisplatin-basedtreatedpatientswithmetastaticNasopharyngealCarcinoma.PLoSOne,2014Nov13;9(11):e112581.(IF=3.234)9)Predictionofoccultcervicallymphnodemetastasisinclinicallynegativesupraglotticsquamouscellcarcinoma.HeadNeckOncol,2012,Oct27;4(3):69.10)PSCAs2294008C>Tandrs2976392G>Apolymorphismscontributetocancersusceptibility:evidencefrompublishedstudies.GenesCancer,2015May;6(5-6):254-64.11)β-葡萄糖神經(jīng)酰胺與HBsAg-DC瘤苗協(xié)同治療肝癌的實(shí)驗(yàn)研究[J/CD].中華普通外科學(xué)文獻(xiàn):電子版,2013,7(4):298-302.12)奧曲肽預(yù)防伊立替康引起的遲發(fā)性腹瀉的臨床研究.新醫(yī)學(xué),2012,43(3):155-158.B：其他排名論著13)ZhouH,WeiJ,DaiQ,WangL,LuoJ,CheangT,WangS.CaCO3/CaIP6compositenanoparticleseffectivelydeliverAKT1smallinterferingRNAtoinhibithumanbreastcancergrowth.IntJNanomedicine,2015Jul1;10:4255-66.(IF=4.383)14)QuMH,ZengRF,FangS,DaiQS,LiHP,LongJT.Liposome-basedco-deliveryofsiRNAanddocetaxelforthesynergistictreatmentoflungcancer.IntJPharm,2014Oct20;474(1-2):112-22.(IF=3.65)15)ChenC,SunP,RongJ,WengHW,DaiQS,YeS.ShortCourseRadiationintheTreatmentofLocalizedRectalCancer:ASystematicReviewandMeta-Analysis.SciRep.2015Jun9;5:10953.(IF=5.578)16)LongJ,ZhouB,LiH,DaiQ,ZhangB,XingS,ZengZ,ChenW,YangJ.ImprovementofHbsAgGene-ModifiedDendriticCell-BasedVaccineEfficacybyOptimizingImmunizationMethodortheApplicationofβ-glucosylceramide.ImmunolInvest.2013Jan16;42(2):137-55.(IF=1.991)17)LongJT,CheangTY,ZhuoSY,ZengRF,DaiQS,LiHP,FangS.Anticancerdrug-loadedmultifunctionalnanoparticlestoenhancethechemotherapeuticefficacyinlungcancermetastasis.JNanobiotechnology.2014Sep30;12(1):37.(IF=4.115)18)王天寶,戴強(qiáng)生,尉秀清,林維浩,石漢平,董文廣.CXCR4RNA干擾序列篩選及對(duì)結(jié)腸癌細(xì)胞SW480生長(zhǎng)的影響[J/CD].中華普通外科學(xué)文獻(xiàn):電子版,2012,6(5):394-399.專著：廣東科學(xué)技術(shù)出版社《實(shí)用胃腸惡性腫瘤診療學(xué)》副主編其他主要工作成績(jī)（比如獲獎(jiǎng)情況）：
未知地區(qū)
